JVM-3 Cells
General information
| Description | JVM-3 is a human B-cell prolymphocytic leukemia (B-PLL) cell line established from the peripheral blood of a 73-year-old Caucasian male patient. The line grows in suspension as lymphoblastoid cells either singly or in loose clumps and is a widely used model for B-PLL, a rare and aggressive mature B-cell leukemia. JVM-3 harbors TP53 mutations (p.Pro1435Leu heterozygous and p.Lys601Asn heterozygous), which inactivate the tumor suppressor function of p53 and are associated with resistance to chemotherapy in B-cell malignancies. The line is cultured in 90% RPMI 1640 + 10% heat-inactivated FBS. JVM-3 is applicable in B-PLL research, including studies of mature B-cell leukemia biology, TP53 mutation-associated drug resistance, BCR signalling pathway analysis, evaluation of targeted therapies (BTK inhibitors, venetoclax, CD20-targeting antibodies), and pharmacological drug screening for B-cell malignancies. It is also used in comparative studies of B-cell leukemia subtypes and as a xenograft model in immunocompromised hosts. |
|---|---|
| Organism | Human |
| Tissue | Peripheral blood |
| Disease | B-cell prolymphocytic leukemia |
| Metastatic site | Peripheral blood (leukemic) |
| Applications | B-cell prolymphocytic leukemia research; mature B-cell leukemia biology; TP53-mutant drug resistance; BTK inhibitor evaluation; venetoclax sensitivity; CD20-targeting antibody testing; B-cell leukemia drug screening |
| Synonyms | JVM3 |
Characteristics
| Age | 73 years |
|---|---|
| Gender | Male |
| Ethnicity | Caucasian |
| Morphology | lymphoblastoid cells growing singly or in clumps in suspension; |
| Cell type | B lymphoblast |
| Growth properties | suspension |
Regulatory Data
| Citation | JVM-3 (Cytion catalog number 305266) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1320 |
Biomolecular Data
| Mutational profile | Mutation: p.Pro1435Leu, Heterozygous; Mutation: p.Lys601Asn, Heterozygous |
|---|
Handling
| Culture Medium | 90% RPMI 1640 + 10% h.i. FBS |
|---|---|
| Supplements | Supplement the medium with 10% heat-inactivated FBS |
| Dissociation Reagent | Not required (suspension culture) |
| Doubling time | ~30 hours |
| Subculturing | Dilute the culture to 2–5 × 10⁵ cells/ml with fresh pre-warmed complete medium every 2–3 days. Count viable cells before passaging. Centrifugation (300×g, 5 min) may be used to exchange medium when needed. |
| Split ratio | 1 to 3 |
| Seeding density | 2 to 5 × 10⁵ cells/ml |
| Fluid renewal | Every 2 to 3 days |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |